Loading...
XNYS
DVA
Market cap11bUSD
Oct 08, Last price  
177.02USD
1D
0.14%
1Q
-23.96%
Jan 2017
175.73%
Name

DaVita Inc

Chart & performance

D1W1MN
XNYS:DVA chart
P/E
15.22
P/S
0.83
EPS
11.63
Div yield, %
—
Shrs. gr., 5y
-6.40%
Rev. gr., 5y
3.39%
Revenues
13.64b
+6.46%
4,880,662,0005,264,151,0005,660,173,0006,108,800,0006,447,391,0006,791,980,0008,186,280,00011,764,050,00012,795,106,00013,781,837,00014,745,105,00010,876,634,00011,404,851,00011,388,479,00011,550,604,00011,618,797,00011,609,894,00012,140,147,00012,815,550,00013,643,069,000
Net income
747m
-20.24%
289,691,000381,778,000374,160,000422,684,000405,683,000478,001,000536,017,000633,446,000723,114,000269,732,000879,874,000663,618,000159,394,000810,981,000773,642,000978,450,000560,400,000691,535,000936,342,000746,803,000
CFO
1.89b
-6.70%
519,571,000533,036,000555,931,000666,710,000839,683,0001,180,046,0001,100,848,0001,773,341,0001,459,407,0001,557,200,0001,963,444,0001,907,449,0001,771,640,0002,072,355,0001,979,028,0001,930,876,0001,564,570,0002,059,031,0002,022,038,0001,886,500,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

DaVita Inc. specializes in delivering essential kidney dialysis treatments and comprehensive renal care to individuals grappling with chronic kidney failure. The company primarily operates an extensive network of outpatient dialysis centers, supplementing this with services provided in hospital inpatient settings and within patients' homes. Beyond direct patient treatment, DaVita manages its own diagnostic laboratories, performing routine tests vital for dialysis patients, alongside other physician-ordered laboratory analyses specifically for those with end-stage renal disease (ESRD). The firm also offers administrative and management support to various other outpatient dialysis facilities. Its broad spectrum of offerings extends to chronic disease management programs, supporting a substantial patient cohort; by year-end 2021, this included 16,000 patients enrolled in risk-based integrated care models and an additional 7,000 in other integrated care arrangements. Further specialized services encompass vascular access interventions, clinical research initiatives, direct physician support, and a complete suite of holistic kidney care solutions. As of December 31, 2021, DaVita's footprint across the United States comprised 2,815 outpatient dialysis centers, collectively serving approximately 203,100 patients. Globally, the company operated 339 outpatient dialysis centers spread across ten countries outside the U.S., attending to roughly 39,900 patients. Moreover, it furnished acute inpatient dialysis services and related laboratory work in around 850 U.S. hospitals. Founded in 1994, DaVita Inc. maintains its headquarters in Denver, Colorado. The company rebranded to its current name in September 2016, having previously been known as DaVita HealthCare Partners Inc.

Related entities

Subsidiaries (2)
DC HEALTHCARE INTERNATIONAL, INC.
TOTAL RENAL CARE, INC.

Key people

Independent Chair of the Board · since 2020
Chief Financial Officer, Treasurer · since 2019
Stephanie Hendrickson
Chief People Officer · since 2025
Christopher Berry
Chief Accounting Officer · since 2023
James Hearty
Chief Compliance Officer · since 2018
David Maughan
Chief Operating Officer - Davita Kidney Care · since 2024
Michael Staffieri
Chief Operating Officer - Emeritus · since 2024
Kathleen Waters
Chief Legal and Public Affairs Officer · since 2021
Chief Executive Officer, Director · since 2019
Independent Director · since 2015
Independent Director · since 2022
Gregory Moore
Independent Director · since 2021
Dennis Pullin
Independent Director · since 2024
Independent Director · since 2022
Independent Director · since 2023
Independent Director · since 2016
IPO date
Oct 31, 1995
Employees
70,000
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Previous name
DAVITA HEALTHCARE PARTNERS INC.

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT